Jean-Paul Scheuer, General Manager, Sanofi Genzyme MCO Lead, Gulf & KSA

21.12.2021
Jean Paul Scheuer, General Manager for Sanofi Genzyme and MCO Lead for Greater Gulf, highlights the company's expanding footprint in the region, the organizational changes brought about by global CEO Paul Hudson, and how Sanofi has managed to launch 20 new products in the last year.
Sanofi has been quick in the registration process thanks to its fantastic regulatory affairs department and has been able to launch products for multiple myeloma, different indications of Dupixent -- asthma, nasal polyps, and atopic dermatitis.
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Saudi Arabia, Vaccines, Rare Diseases, GCC

Related Interviews

Mohamed Mostafa – Vice President and General Manager Saudi Arabia &…

IQVIA Vice President and General Manager Saudi Arabia & Egypt Mohamed Mostafa gives his expert insights into the transformation of the Saudi pharma market in recent years, covering everything from…

Rami Rajab – Chairman, Mecomed

Mecomed is the largest medical devices, imaging, and diagnostics trade association in the Middle East and Africa (MEA). Rami Rajab, chairman, highlights the role of the association in shaping the…

Mohamed Mazen Batterjee – Managing Director, Batterjee Pharma

Mohamed Mazen Batterjee, managing director of Batterjee Pharma, explains how he has turned the business around since joining in 2014, the interplay between the firm’s contract and proprietary manufacturing operations,…

Related Articles

Company Spotlight / Saudi Chemical Company Holding: At the Forefront of Saudi Healthcare’s Evolution

Saudi Chemical Company Holding (SCCH), Saudi Arabia’s leading manufacturer of civil and military explosives, has been expanding its pharma sector footprint in recent years. Today, the company has capabilities across…

Pharma Faces / Mohammed Nasser, Amgen MEA

Seasoned executive Mohamed Nasser currently oversees 16 markets for Amgen across the MEA region, including its most important – Saudi Arabia. He shares some of the key skills that pharma…

Saudi Arabia / IP: Room for Improvement?

While Saudi Arabia is becoming an increasingly attractive investment destination for global pharma, some stakeholders continue to have concerns about whether the country’s intellectual property (IP) protection system is truly…

Latest Report

Denmark Pharma Report 2021

Related Content

Saudi Arabia
Vaccines
Rare Diseases
GCC